$1.04
(Market cap
$6,779 Mln
Revenue (TTM)
$1,211 Mln
P/E Ratio
61.9
P/B Ratio
3.6
Div. Yield
0.7 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
3 %
-
Industry P/E
--
-
EV/EBITDA
29.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.7
-
Face value
--
-
Shares outstanding
156,568,751
10 Years Aggregate
CFO
$2,052.47 Mln
EBITDA
$2,284.27 Mln
Net Profit
$1,548.89 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bio-Techne Corp (TECH)
| -22.7 | -23.2 | -23.4 | -7.5 | -18.3 | 48.7 | 39.7 |
|
BSE Sensex*
| -11.8 | -4.9 | -9.5 | -9.0 | 6.5 | 8.4 | 11.4 |
|
S&P Midcap 400
| 6.6 | -2.1 | -0.8 | 15.6 | 12.9 | 5.8 | 9.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bio-Techne Corp (TECH)
| -18.4 | -6.6 | -6.9 | 925.3 | 62.9 | 44.7 | 51.7 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bio-Techne Corp (TECH)
|
45.5 | 6,779.4 | 1,210.8 | 109.6 | 13.1 | 5.4 | 61.9 | 3.6 |
| 294.3 | 38,315.4 | 4,286.9 | 577.2 | 9.8 | 88.2 | 71.9 | 36.6 | |
| 152.4 | 7,266.1 | 4,027.0 | -184.7 | 11.3 | -5.9 | -- | 2.9 | |
| 107.4 | 23,656.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 31.2 | |
| 173.2 | 28,741.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 21.4 | 4.8 | |
| 45.7 | 19,458.4 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.9 | |
| 630.3 | 73,203.9 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 17 | 2.4 | |
| 566.8 | 24,134.4 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 21 | 4.1 | |
| 48.8 | 7,565.0 | 0.0 | -946.5 | -- | -32.1 | -- | 2.6 | |
| 434.3 | 110,900.3 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 25.9 | 5.6 |
Shareholding Pattern
View DetailsAbout Bio-Techne Corp (TECH)
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments,... Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota. Address: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 Read more
-
CEO, President & Director
Mr. Kim Kelderman
-
CEO, President & Director
Mr. Kim Kelderman
-
Headquarters
Minneapolis, MN
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bio-Techne Corp (TECH)
What is the current share price of Bio-Techne Corp (TECH) Today?
The share price of Bio-Techne Corp (TECH) is $45.47 (NASDAQ) as of 19-May-2026 16:00 EDT. Bio-Techne Corp (TECH) has given a return of -18.26% in the last 3 years.
What is the current PB & PE ratio of Bio-Techne Corp (TECH)?
The P/E ratio of Bio-Techne Corp (TECH) is 61.86 times as on 18-May-2026.
The P/B ratio of Bio-Techne Corp (TECH) is 3.63 times as on 18-May-2026, a 16 discount to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
109.18
|
4.18
|
|
2024
|
68.47
|
5.56
|
|
2023
|
46.33
|
6.72
|
|
2022
|
208.44
|
33.32
|
|
2021
|
525.27
|
47.19
|
What is the 52 Week High and Low of Bio-Techne Corp (TECH)?
The 52-week high and low of Bio-Techne Corp (TECH) are Rs 72.16 and Rs 43.20 as of 20-May-2026.
What is the market cap of Bio-Techne Corp (TECH)?
Bio-Techne Corp (TECH) has a market capitalisation of $ 6,779 Mln as on 18-May-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Bio-Techne Corp (TECH)?
Before investing in Bio-Techne Corp (TECH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.